Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Artgen Biotech PJSC's Days Payable or its related term are showing as below:
MIC:ABIO's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 111.165 * Ranked among companies with meaningful Days Payable only.
Artgen Biotech PJSC's Days Payable
increased
from Jun. 2022 (149.26) to Jun. 2023 (152.84).
It may suggest that Artgen Biotech PJSCdelayed paying its suppliers.
The historical data trend for Artgen Biotech PJSC's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIC:ABIO vs VRTX, REGN, SGEN: Days Payable Comparison
For the Biotechnology subindustry, Artgen Biotech PJSC's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Artgen Biotech PJSC Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Artgen Biotech PJSC's Days Payable distribution charts can be found below:
* The bar in red indicates where Artgen Biotech PJSC's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Artgen Biotech PJSC's Days Payable for the fiscal year that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Artgen Biotech PJSC (MIC:ABIO) has a Days Payable of 152.84 as of Jun. 2023. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Artgen Biotech PJSC and its competitors.
Is Artgen Biotech PJSC's Days Payable too high?
Artgen Biotech PJSC's current Days Payable is 152.84. The Biotechnology industry median Days Payable is 111.17. Artgen Biotech PJSC's value of 152.84 is 37.5% above this industry median. Overall, Artgen Biotech PJSC has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Artgen Biotech PJSC's Days Payable compare to VRTX and REGN?
Artgen Biotech PJSC's Days Payable of 152.84 can be compared against companies in the Biotechnology industry. The industry median Days Payable is 111.17. Artgen Biotech PJSC's value of 152.84 is 37.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 111.17, based on 708 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Artgen Biotech PJSC's current Days Payable of 152.84 is 37.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Artgen Biotech PJSC and its competitors. For the Biotechnology industry, the median Days Payable is 111.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Artgen Biotech PJSC's current Days Payable is 152.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Artgen Biotech PJSC stock overvalued right now?
Artgen Biotech PJSC (MIC:ABIO) has a current Days Payable of 152.84. The current Days Payable is 152.84 and 37.5% above the Biotechnology industry median of 111.17. Artgen Biotech PJSC's overall GF Score™ is 17/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Artgen Biotech PJSC (MIC:ABIO), the current Days Payable is 152.84 as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Artgen Biotech PJSC is a biotechnology company. It is engaged in the drug discovery, research and development and marketing of proprietary products and services in the field of regenerative medicine, bio-insurance, medical genetics, including reproductive genetics, gene therapy, and biopharmaceutics. The company has developed Neovasculgen, which is a gene therapy drug for the treatment of Peripheral Arterial Disease, including Critical Limb Ischemia and also develops SPRS therapy which entails the use of autologous dermal fibroblasts to repair skin damage due to aging and other structural changes.
17GF Score
Get the complete analysis for MIC:ABIO
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIC:ABIO has been successfully added to your 
